News coverage about Aeglea BioTherapeutics (NASDAQ:AGLE) has been trending somewhat negative this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aeglea BioTherapeutics earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.3844158366556 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of equities research analysts have recently issued reports on AGLE shares. Zacks Investment Research upgraded shares of Aeglea BioTherapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research note on Thursday, August 3rd. ValuEngine upgraded shares of Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd.

Aeglea BioTherapeutics (AGLE) traded down 3.70% during mid-day trading on Monday, hitting $4.68. 62,058 shares of the company traded hands. The firm has a 50 day moving average of $3.63 and a 200 day moving average of $4.99. The firm’s market capitalization is $77.00 million. Aeglea BioTherapeutics has a one year low of $2.81 and a one year high of $10.34.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at

Aeglea BioTherapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Insider Buying and Selling by Quarter for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.